Is Sage Therapeutics Inc (NASDAQ:SAGE)’s Fuel Running Low? Reports Show More Sellers

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Investors sentiment increased to 1.95 in 2019 Q1. Its up 0.88, from 1.07 in 2018Q4. It improved, as 27 investors sold Sage Therapeutics, Inc. shares while 47 reduced holdings. 48 funds opened positions while 96 raised stakes. 53.89 million shares or 13.70% more from 47.40 million shares in 2018Q4 were reported.
Partner Fund Limited Partnership stated it has 0.6% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Reliance Trust Of Delaware holds 0.04% or 1,509 shares in its portfolio. Cwm Lc reported 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Regions Fincl accumulated 8 shares or 0% of the stock. Lord Abbett Communications Limited Liability Com has 620,668 shares. Northern Trust Corporation has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Aqr Capital Mgmt Llc invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Ra Capital Ltd Llc invested 2.63% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Timessquare Cap Mngmt Ltd Liability Corp holds 495,200 shares or 0.61% of its portfolio. Thrivent Fincl For Lutherans reported 58,439 shares. Amundi Pioneer Asset Mngmt holds 136,459 shares. State Of New Jersey Common Pension Fund D holds 15,000 shares or 0.01% of its portfolio. Moreover, Riverhead Mgmt Ltd Company has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Tiaa Cref Inv Mngmt Limited Liability Co has 0.04% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 384,925 shares. Moreover, Dimensional Fund Limited Partnership has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE).

The stock of Sage Therapeutics Inc (NASDAQ:SAGE) registered an increase of 15.32% in short interest. SAGE’s total short interest was 5.33M shares in August as published by FINRA. Its up 15.32% from 4.62 million shares, reported previously. With 412,800 shares average volume, it will take short sellers 13 days to cover their SAGE’s short positions.

The stock decreased 2.51% or $4.25 during the last trading session, reaching $165.04. About 336,286 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 6.31% since August 13, 2018 and is uptrending. It has outperformed by 6.31% the S&P500.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $8.44 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The company??s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and Parkinson??s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. SAGE Therapeutics has $249 highest and $170 lowest target. $212.67’s average target is 28.86% above currents $165.04 stock price. SAGE Therapeutics had 14 analyst reports since February 19, 2019 according to SRatingsIntel. The stock has “Buy” rating by Oppenheimer on Tuesday, February 19. The firm earned “Buy” rating on Wednesday, March 20 by Stifel Nicolaus. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Tuesday, February 19 by Cowen & Co. Ladenburg maintained the stock with “Buy” rating in Wednesday, March 20 report. Piper Jaffray maintained the shares of SAGE in report on Wednesday, March 20 with “Buy” rating. The company was maintained on Tuesday, February 19 by Piper Jaffray. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by SunTrust on Wednesday, March 20. The rating was maintained by RBC Capital Markets on Wednesday, February 20 with “Buy”. Morgan Stanley maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Monday, February 25. Morgan Stanley has “Buy” rating and $215 target. Cowen & Co maintained it with “Buy” rating and $207 target in Wednesday, March 20 report.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: which released: “Is Sage Therapeutics a Good Stock to Buy Now? – Nasdaq” on March 20, 2019, also with their article: “Sage Therapeutics Q2 2019 Earnings Preview – Seeking Alpha” published on August 05, 2019, published: “Is Sage Therapeutics’s (NASDAQ:SAGE) 287% Share Price Increase Well Justified? – Yahoo Finance” on July 09, 2019. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: and their article: “7 Disruptive Biotech Stocks to Buy for 2025 –” published on August 01, 2019 as well as‘s news article titled: “Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During “Sage FutureCast” – Business Wire” with publication date: July 24, 2019.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.